Disseminated on behalf of SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) and may include paid advertising.

• While it might not be getting as much attention as other aspects of the current conflicts in Ukraine and the Middle East, GPS jamming is playing a silent, but important role in modern warfare.
• GPS jamming is a warfare tactic that involves using radio frequency noise to overwhelm lower-power signals to disrupt communication, drone navigation, and guided munitions.
• To help combat GPS jamming, SPARC AI has developed next-gen GPS-free target acquisition system and autonomous navigation software for drones and edge devices, to let them fly without relying on GPS.

While issues like drone attacks and heavy artillery strikes steal many of the headlines about the recent conflicts in the Middle East and Ukraine, there’s a hidden battle being fought behind the scenes. This hidden aspect plays a much bigger part of modern conflicts than you might think.

GPS jamming is a tactic where high-powered radio signals are used to block and overwhelm lower-power signals. The purpose of this is to emit enough noise on the same frequency that it disrupts legitimate signals from GPS satellites, often leading to a loss of tracking, navigation failure, and other errors.

It may be used offensively to disorient enemy ship navigation and disrupt communication efforts, but also defensively to form an “invisible shield” around an area of importance, denying precision strikes and/or drones that often rely on GPS to reach their target.

Many aspects of war today rely on communication and tracking via GPS or similar signals, and jamming can cause severe disruptions within these systems, leading to mass confusion, inaccurate navigation, accidents, and much less situational awareness for ground teams.

However, with how prevalent GPS jamming is becoming, and how disruptive it can be during a conflict, some are creating solutions to combat GPS jamming. For example, SPARC AI (CSE: SPAI) (OTCQB: SPAIF) develops GPS-free target acquisition system and autonomous navigation software for drones and edge devices.

The system uses known landmark coordinates to calculate and correct your position to ensure you stay on track, even in areas that are jammed or GPS-denied. 

It determines the geolocation of any visible object using camera telemetry data, and because it’s built on advanced mathematical modeling, the software constructs a 3D understanding of terrain and position to get GPS-level accuracy, without relying on GPS.

The platform integrates without any need for new hardware, works alongside any image navigation system, and by removing the need for specialized hardware like lasers, radar, or lidar, the software may also drone weight, cost, and power use.

As the usage of GPS jamming grows and it keeps disrupting tracking, disabling navigation, and interrupting communications, GPS-free solutions are going to continue to be a popular solution to maintain visibility and awareness, even in challenging environments.

About SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF)

SPARC AI Inc. is a company that develops next-gen GPS-free target acquisition system and autonomous navigation software for drones and edge devices. The technology delivers real-time detection, tracking, and insights without relying on radar, lidar, or heavy sensors. The company aims to redefine situational awareness by merging advanced math, AI modeling, and edge computing into a unified intelligence architecture.

For more information, visit the company’s website at https://sparcai.co.

NOTE TO INVESTORS: The latest news and updates relating to SPAIF are available in the company’s newsroom at https://ibn.fm/SPAIF

• LIXT is developing LB-100, a first-in-class therapy designed to enhance the effectiveness of established cancer treatments while cutting down toxicity
• Strategic partnership with Liora Technologies integrates multimodal oncology data, enabling precision-guided patient care and streamlined clinical trials
• These developments position the company at the intersection of innovation and therapeutics

Lixte Biotech Holdings (NASDAQ: LIXT) is advancing the frontiers of precision oncology, developing therapies that complement existing cancer treatments while integrating cutting-edge data solutions. The company’s lead program, LB-100, is a novel small-molecule compound designed to enhance the efficacy of chemotherapy and radiation, aiming to improve patient outcomes while reducing treatment-related side effects. By focusing on improving the therapeutic index of existing cancer modalities, the company is tackling a recurrent challenge in the field of oncology: maximizing treatment impact while cutting down risks to healthy tissue.

The company recently announced a partnership with Liora Technologies, setting the company up to be a leading force in multimodal oncology data integration. This partnership uses foundation model-based embeddings to unify clinical text, radiology scans, pathology images, and molecular profiles into cohesive patient representations. By blending these complex datasets, the company is strategically positioned to optimize patient selection, streamline clinical trial design, and speed up LB-100’s development in precision oncology. The integration of multimodal data enables researchers to analyze heterogeneous cancer profiles in a unified framework, improving predictive modeling, treatment personalization, and real-world applicability of clinical findings (ibn.fm/rV8gG).

LB-100’s prospect is highlighted by emerging clinical evidence underscoring the value of cutting down treatment-related toxicity. For example, a nationwide phase 3 trial comparing proton beam therapy to traditional photon radiation for oropharyngeal cancer showed that patients experienced fewer side effects while achieving better overall survival. These outcomes show the important impact of minimizing collateral damage during treatment, a principle reflected in LB-100’s mechanism of action, which seeks to sensitize tumors while helping to preserve healthy tissue.

Lixte operates at the nexus of therapeutic innovation and data-driven oncology. The company’s development is guided by the help of thorough preclinical and early clinical data, while the Liora Technologies platform ensures that patient-level insights guide treatment strategy. The blend of multimodal data helps the company move beyond siloed datasets, helping to create useful insights that enable predictive modeling, personalized therapy selection, and enhanced clinical trial efficiency. This approach also ensures flexibility, making analysis possible even when patient records aren’t complete (ibn.fm/X2v4I).

The integration of AI-driven insights with targeted therapeutic development indicates a powerful blend. By ensuring more accurate patient satisfaction and real-time treatment optimization, these multimodal data platforms can improve the commercial and clinical value of oncology drugs. In the case of Lixte, this convergence may lead to more efficient clinical trial design and stronger positioning in an increasingly competitive oncology ecosystem.

These updates highlight Lixte’s broader mission: to deliver futuristic cancer therapies that enhance both patient survival and quality of life. Through the blend of advanced analytics and first-in-class pharmacology, the company strategically positions itself to solve persistent challenges in oncology, such as heterogeneous patient response, treatment resistance, and fragmented clinical data systems. The firm’s R&D strategy emphasizes innovation, which complement existing standard-of-care therapies, instead of competing with them, which may speed up adoption and increase market potential.

For more information, visit the company website at https://lixte.com.

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT

Disseminated on behalf of Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF) and may include paid advertising.

• Canamera Energy Metals seeks to advance a portfolio of rare earth projects across Brazil, USA, and Canada.
• Specifically, the company is looking for rare earth elements (“REEs”), which are a group of 17 metals, useful for defense, high-performance electronics, industrial motors and automation, and several other applications and industries.
• The company recently made several announcement and updates, including announcing positive assay results from the first auger holes at the Turvolândia Rare Earth Project, and signing a letter of intent to potentially acquire an option for another REE project in Brazil.

Canamera Energy Metals (CSE: EMET) (OTCQB: EMETF) is a rare earth and critical metals exploration company that’s focused on developing a portfolio of district-scale mining opportunities across the Americas.

The company holds a diverse portfolio of projects throughout Brazil, USA, and Canada. Canamera’s Brazilian ionic clay projects offer exposure to one of the most underdeveloped and prospective rare earth regions globally. 

Specifically, the company is mining and looking for rare earth elements (“REEs”). These are a group of 17 metals that are split into light rare earth elements (“LREE”) and heavy rare earth elements (“HREE”). LREEs are easier and cheaper to extract, more common to find, and a lower market price due to a more plentiful supply. The 10 metals that are classified as LREEs include: Scandium, Yttrium, Lanthanum, Cerium Praseodymium, Neodymium, Promethium, Samarium and Europium Gadolinium.

HREEs are much less common than LREEs, more complex and costly to extract, and fetch higher prices due to scarcity. The seven HREEs are: Terbium, Dysprosium, Holmium, Erbium, Thulium, Ytterbium and Lutetium.

These metals have a variety of use cases in industries like defense and aerospace, electronics, industrial motors and automation, oil and gas, medical imaging and diagnostics, and strategic supply chain security.

A few of the things these metals are used to create include:

• Permanent magnets for EV motors, wind turbines, aircraft actuators, naval propulsion, and precision guided weapons.
• Phosphors for displays, LEDs, laser targeting, night vision systems, and more.
• Petroleum refining catalysts, alloy strengthening, ceramics, and glass polishing.
• Nuclear control rods, neutron shielding, MRI contrast agents, and cancer therapy isotopes.
• Robotics, factory automation, and high-efficiency motors in manufacturing.

Canamera Energy Metals recently reported several developments highlighting progress across its rare earth portfolio. The company confirmed ionic clay rare earth element (“REE”) mineralization at its Turvolândia rare earth project in Brazil, reporting positive assay results from the first 27 of 55 completed auger holes. Notably, nine of the 27 holes were halted in elevated total rare earth oxide (“TREO”) zones due to ground conditions, suggesting that mineralization may remain open at depth and warrant further exploration.

In a separate announcement, the company disclosed that it has signed a non-binding letter of intent (“LOI”) with a Brazilian mineral permits holder that could provide an option to earn a 100% interest in the Patos ionic clay REE project in Minas Gerais, Brazil. The project consists of eight exploration permits covering approximately 15,979 hectares (about 39,484 acres), further expanding the company’s footprint in one of the world’s emerging rare earth districts.

For more information, visit the company’s website at CanameraMetals.com.

NOTE TO INVESTORS: The latest news and updates relating to EMETF are available in the company’s newsroom at ibn.fm/EMETF

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

This document contains “forward-looking information” within the meaning of applicable securities legislation, including statements regarding: the Company’s planned exploration activities on its projects; the anticipated timing and completion of the earn-in milestones under the Option Agreement; the Company’s ability to make required cash and share payments and incur required exploration expenditures; the geological prospectivity of its projects; and the Company’s exploration strategy.

Forward-looking information is based on assumptions, estimates, and opinions of management at the date the statements are made and is subject to a variety of risks and uncertainties that could cause actual results to differ materially from those anticipated or projected. These assumptions include, without limitation: the Company’s ability to raise sufficient capital to fund its exploration programs and option payments; favourable regulatory conditions; continued access to its projects; and general economic conditions.

Important risk factors that could cause actual results to differ materially include, but are not limited to: uncertainties related to raising sufficient financing; the inherently speculative nature of mineral exploration; title risks; environmental and permitting risks; and fluctuations in uranium prices. Additional risk factors affecting the Company can be found in the Company’s continuous disclosure documents available at www.sedarplus.ca.

Readers are cautioned not to place undue reliance on forward-looking information.

• ETST is focused on compounding pharmacies, telemedicine, and clinical services
• Vertically integrated model supports recurring, patient-driven revenue
• The company’s strategy aligns with increased demand for personalized and digital healthcare

Earth Science Tech (OTC: ETST) is consolidating on its identity as a leading healthcare holding company, implementing a strategy built on vertical integration across telemedicine, pharmaceuticals, and clinical services. The company’s transitioning from legacy operations highlights a distinct alignment with high-growth segments of the healthcare sector, particularly personalized medicine and digital care delivery (ibn.fm/9lMJg).

At the nucleus of ETST’s model are its compounding pharmacy operations, which produce customized medications tailored for specific patient needs. This segment aims to tackle the growing gap in traditional pharmaceutical manufacturing. Where standardized drug testing usually falls short of patient-specified requirements. Through operating licensed compounding facilities, the company is strategically positioned to serve a niche but quickly evolving market driven by demand for precision treatment and specialized formulations.

This segment tackles a quickly expanding gap in conventional pharmaceutical manufacturing, where standardized drugs usually fall short of patient-specific requirements. By running licensed compounding facilities, Earth Science Tech is strategically positioned to serve a growing market driven by a demand for precision treatment and specialized formulations.

In addition to this, the company’s telemedicine infrastructure operates as a front-end patient acquisition and engagement platform. Through virtual consultations and prescription management, the company efficiently connects patients to pharmacy services, helping to create a seamless pathway to treatment from diagnosis. This integration improves convenience while improving retention and lifetime patient value.

ETST also strengthens its platform by using clinical service operations that support patient coordination and care continuity. Together, these segments help create a connected ecosystem that enables the company to engage across different points of the healthcare value chain, which is an increasingly important advantage in a space fast-moving toward integrated care models.

For investors, this approach draws its strength from its scalability and revenue structure. Telemedicine helps drive up patient inflow, while pharmacy services help generate recurring revenue through ongoing prescriptions. This helps create a compounding effect where each patient can translate into sustained, long-term revenue streams. Also, vertical integration gives better control over margins, operations, and compliance.

The company’s recent financial records underscore this strategic direction, with consistent revenue growth backed by expansion cutting across its healthcare segments. With the scale in operations, ETST seems to be improving efficiency while reinforcing its core business model.

Looking forward, several industry tailwinds support the company’s positioning. Telehealth adoption continues to grow, personalized medicine is getting more attention, and healthcare systems are focusing more on cost efficiency and accessibility. These trends directly align with the company’s integrated platform, which was created to deliver convenient and efficient care.

For more information, visit EarthScienceTech.com.

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST

• TechForce Robotics are advancing automation through a subscription-based RaaSP (Robotics-as-a-Service Provider)
• The company delivers a fully managed autonomous robotics ecosystem with no upfront capital burden
• The model enables scalable, predictable, and revenue-aligned deployment across service industries

As artificial intelligence and robotics transition from experimental innovation into real-world deployment, the economics of automation are undergoing a fundamental transformation. Nightfood Holdings Inc. (OTCQB: NGTF), acting through its subsidiary TechForce Robotics, is leveraging this evolution by advancing RaaSP, a platform that eliminates a major impediment to adoption: upfront capital expense (ibn.fm/bmrvL).

Within the past few years, the service industry has taken a sharp turn into the world of technology to improve efficiency within the workplace. This approach allows companies to keep up with a fast-paced lifestyle, while making the guest experience much more enjoyable. Traditionally, automation services require significant capital investment, ongoing maintenance commitments, and long procurement cycles. These challenges limit adoption to large enterprises capable of absorbing financial risk. RaaSP changes this equation by transforming automation from a capital expenditure into an operating expense, making it possible for organizations to deploy robotics through trackable monthly subscriptions instead of large upfront payments.

TechForce Robotics functions as a fully managed platform, blending cloud-based software, autonomous robots, deployment, mapping, training, and ongoing optimization into one service offering. With this approach, customers can introduce automation quickly while avoiding the challenges that come with ownership, infrastructure, and technical integration.

A unique feature of this is that the financial advantages are measurable and immediate. Businesses can avoid lengthy capital approval cycles and deploy automation in alignment with the demands of operation. This flexibility is crucial in industries such as logistics, hospitality, and healthcare, where labor constraints and an increase in operational costs continue to increase the need for efficiency. Through the alignment of costs with usage, RaaSP helps organizations incrementally scale automation while ensuring financial agility.

For investors, this model underscores a compelling evolution in revenue generation. Subscription-based pricing creates recurring revenue streams, offering greater predictability and long-term visibility compared to traditional equipment sales. This model also helps improve customer lifetime value, as ongoing service, optimization, and maintenance foster deeper, enduring client relationships.

TechForce Robotics also seeks to solve one of the most persistent issues in robotics adoption: deployment complexity. The company takes care of the full lifecycle of implementation, including site mapping, evaluation, routing, onboarding, and continuous performance refinement. This fully managed approach eliminates the need for in-house technical expertise, greatly reducing barriers to entry and speeding up adoption timelines (ibn.fm/l36BK).

Organizations can expand robotic deployments across departments and locations using unified platforms, adjusting capacity as workflows evolve. With this modular flexibility, customers are able to validate return on investment before scaling, while giving NGTF needed opportunities for expansion within existing accounts.

Its modular autonomous robot, TIM-E (pronounced “Timmy”), is designed to transport items across large, complex facilities, using interchangeable attachments to handle back-of-house logistics like inventory delivery, linen movement and waste collection, allowing operations to scale without replacing core systems. Alongside this, the company deploys an automated beverage dispensing system, BIM-E (Beverages in Motion – Everywhere), built for high-traffic environments, delivering consistent pours across a range of drinks while reducing waste and maintaining speed during peak demand. Together, these systems are designed to streamline repetitive tasks, improve operational flexibility, and enable staff to focus more on customer-facing responsibilities.

Regular software updates and maintenance ensure that deployed systems remain current without needing added capital investment. This future-ready approach protects customers from technological obsolescence while reinforcing the long-term value of the subscription model.

The evolving industry landscape highlights the importance of this shift. As service robotics tilts toward large-scale commercialization, companies capable of delivering reliable, scalable, and cost-efficient solutions are coming up as key infrastructure providers. TechForce Robotics is aligning with this growth trajectory by blending AI-driven robotics with a flexible, revenue-focused deployment framework.

For more information, visit the company’s website at TechForceRobotics.com.

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at https://ibn.fm/NGTF

• American Fusion Inc. has officially changed its corporate name and ticker symbol from Renewal Fuels (OTC: RNWF) to AMFN.
• The move follows the company’s earlier merger with Kepler Fusion Technologies and reflects its focus on the company’s unique fusion energy technology development.
• Kepler’s Texatron(TM) platform is designed as a modular system for industrial and commercial energy deployment, pursuing a strategy that initially targets “behind-the-meter” power generation at customer facilities.
• A 5-megawatt demonstration system and a 100-megawatt commercial-scale design are currently under development.
• The rebranding is intended to align the company’s public market presence with its long-term technology and infrastructure strategy.

American Fusion (OTC: AMFN), an advanced energy platform company focused on the development and commercialization of fusion energy technologies has formally completed a corporate name and ticker symbol change that signals the company’s transition toward fusion energy development. The Texas-based company, formerly known as Renewal Fuels, Inc., began trading under its new identity and ticker symbol AMFN on March 19, after the action was processed by the Financial Industry Regulatory Authority (https://ibn.fm/YYMqG).

The change was listed on FINRA’s daily corporate action report the previous day and represents what the company describes as a key step in its transformation following a merger with Kepler Fusion Technologies.

According to the company’s announcement, the rebranding is intended to align its public market identity with a strategic focus on developing and commercializing fusion-based energy systems. 

American Fusion’s strategy centers on advancing technology developed by Kepler Fusion Technologies, now a wholly owned subsidiary. The subsidiary is developing the Texatron(TM) system, a concept aimed at producing modular fusion energy units that could be deployed for industrial or commercial power applications.

Management says the goal is to create an “infrastructure-grade” energy platform capable of delivering scalable power solutions in environments where electricity supply is constrained or where dedicated generation capacity is required.

Chief executive and chairman Richard C. Hawkins described the name and ticker change as an important milestone in aligning the company’s market identity with its operating strategy.

“With the completion of our name and ticker change, we are now fully aligned with the American Fusion platform and our long-term strategy,” Hawkins said in the company’s announcement. “Our focus is on advancing Kepler’s Texatron technology toward commercial deployment and building a scalable, infrastructure-grade energy platform positioned to address global demand for next-generation power solutions.”

The company says it will continue to update investors as it advances technology development, intellectual property initiatives and regulatory work tied to its commercialization plans.

At the center of the company’s technical effort, the Texatron platform is designed around aneutronic fusion concepts and is being engineered as a modular reactor architecture. While fusion energy remains in a development stage across the industry, the company reports progress toward demonstrating operational systems that could eventually serve industrial facilities or localized power needs.

Brent Nelson, who also serves as a director of American Fusion, said the corporate restructuring establishes a clearer platform for advancing the technology toward potential commercial deployment. “With the American Fusion platform now fully established, we are positioned to accelerate the advancement of the Texatron system toward commercial deployment,” Nelson said. “Our focus is on execution, delivering a scalable, infrastructure-grade fusion solution capable of addressing real-world energy demand.”

The company is currently developing several Texatron designs intended to support different power requirements. Kepler is working on nine variations of the Texatron system and is constructing two prototype reactor configurations: a 5-megawatt demonstration unit and a 100-megawatt model intended to test commercial viability.

The larger design forms the basis of the company’s early commercialization strategy. Because the reactors are intended to operate in modular units, additional capacity could be added incrementally as demand grows.

Under that model, ten 100-megawatt reactors would produce roughly one gigawatt of generation capacity, a scale that investors and infrastructure planners commonly use when evaluating large power projects.

Rather than focusing initially on connecting power plants to large public grids, the company plans to target behind-the-meter deployments. In energy markets, behind-the-meter systems supply electricity directly to the facility where they are installed, bypassing the broader grid infrastructure. This approach can reduce regulatory complexity and speed up project timelines.

Nelson said that in certain jurisdictions, including Texas, installing generation capacity directly at a customer site can simplify permitting and interconnection requirements compared with traditional utility-scale projects. That strategy is expected to address industrial facilities, data centers, or other large energy users seeking reliable power capacity independent of regional grid constraints.

For more information, visit the company’s website at www.AmericanFusionEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to AMFN are available in the company’s newsroom at https://ibn.fm/AMFN

• The company is developing an institutional Digital Asset Treasury model focused on enabling corporations to manage and generate yield from Bitcoin holdings.
• Its ecosystem integrates multiple verticals, including AdTech, InsurTech, AI Governance, and ClimateTech, within a unified blockchain-enabled framework.
• The $NILA token serves as a central mechanism for governance, incentives, and interoperability across the platform.
• The company operates across several large and expanding markets, including decentralized finance, digital advertising, artificial intelligence, and sustainability-focused finance.
• Its structure as a publicly traded entity combined with a decentralized ecosystem positions it to pursue both institutional adoption and broader ecosystem participation.

MindWave Innovations (NYSE American: APUS) is a digital asset and technology company providing institutional-grade treasury infrastructure for the digital asset economy. The company offers a secure and compliant gateway to digital assets through insured custody solutions, AI-enabled yield strategies, and transparent reporting systems. MindWave is focused on supporting corporations and institutional counterparties in holding, managing, and generating risk-aware yield on Bitcoin reserves through a disciplined, technology-driven platform.

The company’s strategy is built around a multi-vertical ecosystem that integrates Bitcoin-based treasury infrastructure with AI-driven yield capabilities, digital engagement platforms, and sustainability-focused systems. Its platform is designed to support both institutional participants—through compliant, insured digital asset management and treasury solutions—and a broader community through a decentralized, token-driven ecosystem enabling governance, staking, and access to financial services. This approach is supported by a blockchain-enabled architecture designed to align economic incentives, governance, and value flow across its operations through the use of its native token, $NILA.

Following a strategic business combination, the company now operates as a publicly traded platform positioned at the intersection of digital assets, artificial intelligence, and decentralized systems. Its structure brings together institutional treasury solutions with a broader ecosystem designed to support yield generation, governance, and real-world utility.

The company is headquartered in Delaware.

Products

The company’s operations are centered on MindWaveDAO, a decentralized ecosystem developed through its UAE-based subsidiary and designed to integrate multiple functional verticals into a unified blockchain-enabled platform.

At the core of the ecosystem is a Bitcoin-based yield infrastructure that underpins financial activity across the platform, supporting yield generation, staking mechanisms, and overall economic sustainability. This foundation is complemented by an institutional-grade treasury framework that enables corporations to directly hold digital assets through segregated, board-controlled custody structures designed to align with corporate governance and compliance requirements.

The broader platform architecture includes multiple integrated components designed to support institutional and on-chain financial activity. These include a proprietary Layer-2 blockchain (“MindChain”) engineered for real-world asset tokenization and scalable decentralized finance applications; a multi-layered security framework incorporating distributed key management, insured custody structures, and policy-based controls; and a validator node infrastructure that supports Proof-of-Stake networks while generating recurring, protocol-driven yield.

In addition, the platform incorporates an AI-powered yield engine that leverages data ingestion, signal generation, and automated strategy execution to identify market opportunities and manage risk across digital asset markets. This system supports a diversified, multi-strategy approach that includes derivatives-based income strategies, liquidity provisioning, and volatility-driven trading.

On top of this infrastructure, the ecosystem is organized across four primary application verticals:

• AdTech (Wave+): A platform that converts digital engagement into tokenized incentives through a tap-to-earn model tied to sustainability-linked activities, enabling users to earn rewards through participation in tasks and interactions.
• InsurTech: A hybrid framework combining on-chain smart contract mechanisms with traditional underwriting structures to provide protection for digital assets and address risks associated with volatility and custody.
• AI Governance: A cognitive analytics layer designed to support decision-making, strategic analysis, and governance participation by providing structured insights and analytical tools within decentralized environments.
• ClimateTech (Aquae Impact): A system focused on the tokenization of ecological and carbon-related assets, enabling transparent and auditable tracking of environmental impact through blockchain-based verification.

Across all verticals, the $NILA token functions as the central economic layer, facilitating governance participation, staking, service activation, and interoperability throughout the ecosystem.

Market Opportunity

The company operates at the convergence of several large and rapidly growing markets, including decentralized finance, digital advertising, artificial intelligence, insurance technology, and sustainability-focused finance.

The decentralized finance (“DeFi”) market continues to expand, with total value locked expected to reach hundreds of billions, supporting growth in yield generation and decentralized financial infrastructure, while global digital advertising spend is projected to surpass $650 billion, reflecting increasing demand for transparency, performance alignment, and measurable engagement outcomes.

At the same time, demand for digital asset insurance solutions is increasing alongside the growth and volatility of cryptocurrency markets, artificial intelligence is projected to generate trillions in economic impact across industries, and climate finance markets are expanding as regulatory pressures and investor demand drive interest in transparent, ESG-aligned investment opportunities.

Leadership Team

Dr. Vin Menon, CEO of MindWaveDAO, is a globally recognized blockchain strategist and social entrepreneur committed to applying technology to sustainable development initiatives. He leads the company’s vision of building an institutional-grade digital treasury and yield ecosystem that integrates decentralized finance with real-world utility and environmental alignment. In addition to his role at MindWaveDAO, he is Co-founder and CEO of AQUAE, where he developed a framework for transforming ecological assets into measurable and tradable digital instruments, and he has advised and supported multiple ventures across Web3, DeFi, and digital asset markets.

Capt. Sandeep Yadav, COO of MindWaveDAO, brings more than 20 years of experience across financial markets, fintech, and global operations, with a background spanning maritime leadership, regulatory compliance, and sustainability-focused strategy. He has held senior operational roles across international shipping and logistics, overseeing complex global operations and compliance frameworks, and currently contributes to strategy and climate-focused initiatives through his work with Aquae Labs and related organizations.

Amardeep Singh, CTO of MindWaveDAO, has over 27 years of experience in the technology industry, including more than eight years specializing in blockchain systems. His background includes work across satellite communications, healthcare, and fintech, where he has led the design and implementation of enterprise-scale systems, with expertise in IT security, technical architecture, and the delivery of complex, cross-functional technology solutions.

For more information, visit the company’s website at www.MindWavedao.com.

NOTE TO INVESTORS: The latest news and updates relating to APUS are available in the company’s newsroom at https://ibn.fm/APUS

• The announcement outlines a strategic collaboration between HeartBeam and Mount Sinai to develop and validate AI-based ECG Algorithms
• The collaboration is focused on building next-generation, personalized AI-ECG algorithms for wellness and clinical applications, including assessing heart attack risk
• HeartBeam’s role in this evolving landscape is anchored by its HeartBeam System

HeartBeam (NASDAQ: BEAT) recently announced a collaboration with Mount Sinai aimed at advancing artificial intelligence-driven electrocardiogram technology, marking another step in the company’s push to expand its role in next-generation cardiac monitoring. The announcement highlights HeartBeam’s growing focus on artificial intelligence (“AI”)-enabled analysis and reinforces the relevance of its technology as healthcare increasingly shifts toward data-driven, remote monitoring solutions.

The announcement outlines a strategic collaboration between HeartBeam and Mount Sinai to develop and validate high value, AI-based ECG algorithms that can be deployed broadly across HeartBeam’s platform. These AI models may include patient-relevant wellness insights, condition-focused assessments, and applications for chronic condition management. 

The importance of developing and validating AI-ECG algorithms continues to grow as cardiovascular disease remains a leading cause of mortality worldwide. Traditional ECG interpretation can be time consuming and subject to variability, while AI-driven approaches offer the potential to enhance accuracy, reduce diagnostic delays and uncover subtle patterns that may not be easily recognized by clinicians. 

At the core of this collaboration is the combination of HeartBeam’s proprietary signal acquisition technology and Mount Sinai’s clinical expertise. HeartBeam’s unique ability to generate longitudinal, high-fidelity synthesized 12-lead ECG datasets from patients in the home setting—data that has historically been inaccessible to AI development – creates a foundation for developing increasingly personalized algorithms earlier in the care journey and enabling 12-lead ECG assessments in real-world settings.

By leveraging longitudinal, real-world synthesized 12-lead ECG data rather than isolated clinical snapshots, the collaboration has the potential to significantly expand the addressable market for AI-driven cardiac monitoring. The collaboration could unlock new opportunities in preventive cardiology, chronic disease management, and remote patient monitoring—further reinforcing HeartBeam’s position as a leader in cardiac intelligence platforms.

HeartBeam’s role in this evolving landscape is anchored by its HeartBeam System, which is the first cable-free, high-fidelity ECG system capable of capturing the heart’s electrical signals from three non-coplanar dimensions for arrhythmia assessment. The system has received U.S. Food and Drug Administration (“FDA”) clearance for arrhythmia assessment and is designed to provide a more comprehensive view of cardiac electrical activity than traditional single-lead devices, enabling richer datasets for analysis and interpretation. This multidirectional signal capture is particularly valuable for AI applications, as more robust data inputs can improve algorithm performance and reliability.

Moreover, the company’s technology integrates embedded electrodes into a compact, handheld device, allowing patients to record ECG signals wherever they are without adhesive patches or wires. This design simplifies use while maintaining clinical-grade signal quality, making it well-suited for remote monitoring. 

The collaboration with Mount Sinai builds on this foundation by providing access to clinical datasets necessary to train and validate AI models. Validation is a critical step in the development of medical AI, ensuring that algorithms perform reliably across diverse patient populations and clinical scenarios. Without rigorous validation, even promising AI tools may struggle to gain regulatory approval or clinical adoption. By working with a leading academic medical center, HeartBeam is positioning its technology within a framework that prioritizes clinical rigor and real-world applicability.

Beyond improving accuracy, AI-ECG algorithms have the potential to transform how cardiac care is delivered. Remote monitoring platforms that incorporate AI can enable continuous assessment of patients, allowing clinicians to detect changes earlier and intervene before conditions worsen. This approach aligns with broader healthcare trends emphasizing preventive care, decentralized assessments and the integration of digital technologies into routine clinical practice.

HeartBeam’s collaboration also reflects a strategic effort to expand the capabilities of its platform beyond its current indications. As AI models become more sophisticated, they have potential to support new use cases such as predicting future cardiac events, identifying ischemic changes or stratifying patient risk. These capabilities could open additional pathways for growth and broaden the clinical impact of the company’s technology. As HeartBeam continues to develop and validate AI-driven solutions in partnership with leading institutions, its efforts underscore the growing convergence of medical devices, data analytics and artificial intelligence in shaping the future of cardiovascular care.

For more information, visit www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

Disseminated on behalf of CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF) and may include paid advertising.

• CMX Gold & Silver Corp., an exploration-stage company advancing the historic Clayton Silver Mine in Idaho, sees compelling prospects for unexplored areas of the project, magnified by the growing value of silver
• According to J.P. Morgan Global Research, silver prices are projected to average $81/oz in 2026, double their average in 2025, encouraging aggressive exploration of the historically productive but largely unexplored site
• In January 2026, the company commenced a non-brokered private placement financing for aggregate gross proceeds of up to CAN$2,000,000

CMX Gold & Silver (CSE: CXC) (OTC: CXXMF), an exploration-stage company advancing the historic Clayton Silver Mine in Idaho, recognizes that global demand and geopolitical factors are further boosting silver prices. To capitalize on this growth, the company is moving forward with the exploration of its flagship Clayton Silver project in Idaho, a 1,028-acre property with 29 patented mining claims, 2 patented mill sites, and 20 unpatented claims (https://ibn.fm/6SkLE).

The mine once ranked as the most active underground mine in the district, producing silver, along with lead, zinc, minor gold, and copper (https://ibn.fm/j21FN). However, the Clayton mine was never fully explored. It was only mined along a single vein because no more ore was needed for the small mill operation. But the site represents a dolomite limestone deposit, uplifted when the mountains were formed. Geology suggests a high probability that there are other undiscovered cracks in the overall deposit, cracks into which geothermal fluids would have flowed and deposited minerals, just as they were in the original producing vein. As a result, the company sees it as highly improbable that the single partially mined vein was the only silver vein there.

Today, despite the typical ups and downs of mineral prices, the surge in silver prices, along with the property’s promising geology and history, is driving the company’s Clayton Silver Mine activity. According to J.P. Morgan Global Research, silver prices rose by over 130% in 2025, primarily driven by industrial demand along with uncertainty over tariff regulations and global economic pressures on currencies. According to the research conducted, silver prices are expected to average $81/oz in 2026, double their average in 2025 (https://ibn.fm/CiZLA).

Given silver’s critical role in multiple industrial processes, along with international economic stresses on currencies, silver demand is expected to continue rising longer-term, exacerbating a large structural supply deficit. Today, industrial applications account for greater than 60% of total demand, with requirements relentlessly increasing for solar panels, AI buildout and military applications (missiles, etc.). All of this places CMX in a strong position for financing an impactful exploration program.

In January 2026, the company announced a non-brokered private placement financing for aggregate gross proceeds of up to CAN$2,000,000. The proceeds are for a geophysical survey and an initial diamond-drilling program on the property, bringing life to a mine that was never fully explored (https://ibn.fm/QoVms).

The company is off to a great start in 2026 and is on track to have its best year yet.

For company information, visit the company’s website at www.CMXGoldandSilver.com.

NOTE TO INVESTORS: The latest news and updates relating to CXXMF are available in the company’s newsroom at https://ibn.fm/CXXMF

• A landmark Phase III trial published in The Lancet demonstrated a five-year overall survival rate of 90.9% for oropharyngeal cancer patients treated with proton therapy, compared with 81% for those receiving traditional radiation
• Proton therapy’s ability to stop at a precise depth within the body reduces radiation exposure to surrounding healthy tissue, a clinical advantage driving new facility investments across the U.S., including a proton center scheduled to open this summer in Boca Raton, Florida
• LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) implemented some cohesion beyond pharmaceuticals in November 2025 with the acquisition of Liora Technologies Europe Ltd., now a subsidiary of LIXTE and developer of the electronically controlled LiGHT proton therapy platform

For decades, radiation oncology advanced incrementally, improving precision through software and delivery techniques while the underlying physics of photon radiation remained largely unchanged. The core limitation persisted: photon beams pass through the body, leaving an exit dose of radiation in tissue beyond the tumor. The question oncologists repeatedly returned to was not whether this collateral exposure mattered, but how much it mattered over a patient’s lifetime. A landmark study published in The Lancet in December 2025 offered some of the clearest evidence yet, and the findings are beginning to influence how cancer treatment infrastructure is being planned.

A Survival Gap That Changes Conversation

The University of Texas MD Anderson Cancer Center led the largest randomized Phase III trial to date comparing proton therapy to traditional radiation therapy in patients with oropharyngeal cancer. The study enrolled 440 patients across 21 proton centers in the U.S. and tracked outcomes over five years.

Patients treated with intensity-modulated proton therapy achieved a five-year overall survival rate of 90.9%, compared with 81% for those receiving conventional photon radiation therapy. In oncology, a nearly ten-percentage-point survival difference over five years represents a meaningful clinical outcome.

Beyond survival, the proton cohort experienced lower rates of treatment-related complications. Difficulty swallowing, feeding tube dependence, dry mouth and severe decreases in immune cell counts were all reduced compared with traditional radiation therapy. These are not minor quality-of-life details; they influence how patients recover, tolerate additional treatments and maintain daily function after therapy.

Taken together, the results provide some of the strongest randomized evidence to date supporting proton therapy’s potential advantages for certain cancer populations.

Infrastructure Is Following Science

Clinical evidence of this magnitude often influences capital investment in healthcare infrastructure, and radiation oncology is beginning to reflect that shift.

In March 2026, the Eugene M. & Christine E. Lynn Cancer Institute at Boca Raton Regional Hospital, part of Baptist Health, announced plans to open a new proton therapy center later this year. The facility is expected to expand access to precision radiation treatment across Palm Beach County.

Physicians involved in the program noted that having both proton and photon radiation therapy available under one roof allows oncologists to tailor treatment plans to each patient’s anatomy, cancer stage and long-term risk profile. In many cases, proton therapy may provide an additional layer of protection for nearby organs such as the heart, spinal cord or salivary glands.

As more clinical data emerges and hospitals evaluate long-term patient outcomes, access to proton therapy is increasingly viewed as part of the evolving toolkit of modern radiation oncology.

LIXTE and the LiGHT System: Positioned at the Intersection

LIXTE Biotechnology Holdings, Inc. (NASDAQ: LIXT), headquartered in Boca Raton, Florida, spent 2025 expanding its presence across multiple segments of oncology innovation.

The company is best known for its clinical-stage pharmaceutical pipeline built around LB-100, a first-in-class inhibitor of protein phosphatase 2A (“PP2A”). Rather than replacing established cancer therapies, LB-100 is designed to enhance their effectiveness. By inhibiting PP2A, the compound stimulates cell-cycle progression and interferes with DNA repair in cancer cells, potentially making tumors more responsive to chemotherapy and immunotherapy. LB-100 is currently being evaluated in multiple clinical programs targeting solid tumors with significant unmet medical need, including ovarian clear cell carcinoma, metastatic colon cancer and advanced soft tissue sarcoma.

In November 2025, LIXTE expanded beyond drug development through the acquisition of Liora Technologies Europe Ltd., now operating as a subsidiary of LIXTE and the developer of the LiGHT System, an electronically controlled proton therapy platform. Unlike conventional proton systems that rely on large cyclotrons or synchrotrons, electronically controlled accelerator technologies aim to improve flexibility and potentially reduce the infrastructure footprint associated with proton therapy facilities.

For LIXTE, the acquisition creates strategic optionality: participation in the expanding proton therapy ecosystem while continuing to advance a pharmaceutical pipeline designed to enhance the effectiveness of existing cancer treatments.

Convergence in the Next Phase of Oncology

The future of cancer treatment increasingly lies in integration rather than isolated breakthroughs. Precision radiation, immunotherapy, targeted drugs and advanced diagnostics are being combined in ways that were difficult to imagine even a decade ago.

Proton therapy’s emerging clinical evidence and expanding infrastructure reflect one side of that transformation. On the other, companies developing therapies designed to improve the effectiveness of existing treatments are exploring how those therapies may fit within a broader, multi-modal oncology ecosystem.

As these technologies continue to converge, the intersection between precision radiation and treatment-enhancing therapeutics may represent one of the more important frontiers in cancer care.

For more information, visit the company website at https://lixte.com.

NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT